In June 2026, India's Central Drugs Standard Control Organisation (CDSCO) issued a directive requiring all pharmaceutical manufacturers in India to maintain a robust pharmacovigilance system for reporting adverse events (AEs)…
India has set ambitious goals for its pharmaceutical sector: becoming the "pharmacy of the world" for generic medicines, expanding into complex generics and biosimilars, and boosting exports to $50 billion…
India's pharmaceutical regulatory framework has undergone significant transformation in recent years, with the Central Drugs Standard Control Organisation (CDSCO) and the Pharmacovigilance Programme of India (PvPI) playing increasingly active roles…
On May 21, 2026, India's Central Drugs Standard Control Organisation (CDSCO) issued a clear directive: no injectable product can be classified or sold as a cosmetic. The directive, reported by…